Gastrografin
Colonic Neoplasms
University of Roma La SapienzaN/ADormant
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 81/ 100
Competitive context
21 Active assets in the Colonic Neoplasms cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Eloxatin First Affiliated Hospital of Guangxi Medical University | Phase 4 | BBB |
PROPOFOL Hillel Yaffe Medical Center | Phase 4 | BB |
Ertapenem University of Ulm | Phase 4 | BB |
Levoleucovorin Asan Medical Center | Phase 2 | BB |
Sevoflurane Uppsala University | Phase 4 | BB |
View all 50 →
Same molecule, other indications
Gastrografin is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →